GAITHERSBURG, Md., Oct. 9 /PRNewswire-FirstCall/ -- MedImmune, Inc. today announced that a resale registration statement has been filed on Form S-3 with the Securities and Exchange Commission in connection with its recent sale of $575 million principal amount of 1.375% Convertible Senior Notes due 2011 and $575 million principal amount of 1.625% Convertible Senior Notes due 2013. The registration statement became effective automatically upon filing. The sale of $1.15 billion notes to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), was completed in June 2006. A copy of the prospectus relating to the notes can be found on the Securities and Exchange Commission’s website.
This press release does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification of the securities under the securities laws of any such state.
MedImmune, Inc.
CONTACT: Investors: Peter Vozzo, +1-301-398-4358, or Media: Kate Barrett,+1-301-398-4320, both of MedImmune, Inc.
Web site: http://www.medimmune.com//
